team members

Andrew Anzalone

MD, PhD

Co-founder and Head of Prime Editing Platform

Andrew Anzalone joined Prime Medicine in 2020 as the head of the prime editing platform, where he currently leads efforts to advance technological developments in prime editing for human therapeutic applications.

Dr. Anzalone received his Sc.B. degree in chemistry from Brown University, where he performed undergraduate research in synthetic organic chemistry. He completed his M.D. and Ph.D. degrees at Columbia University as part of the Medical Scientist Training Program. Dr. Anzalone’s thesis research in Virginia W. Cornish’s laboratory focused on the design and synthesis of fluorescent probes for biological imaging applications, and on the investigation and engineering of RNA-dependent protein translation reprogramming mechanisms in eukaryotes. After completing his graduate studies, Dr. Anzalone pursued postdoctoral research as a Jane Coffin Childs Memorial Fund Postdoctoral Fellow in the laboratory of David R. Liu at the Broad Institute of Harvard and MIT. In the Liu laboratory, Dr. Anzalone pioneered the development of prime editing, a novel search-and-replace gene editing technology that has the potential to correct the majority of known human genetic variants associated with disease.